國家衛生研究院 NHRI:Item 3990099045/13796
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 915214      在线人数 : 1379
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13796


    题名: INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
    作者: Pavlakis, N;Shitara, K;Sjoquist, K;Martin, AJ;Jaworski, A;Yip, S;Oh, DY;Moehler, M;Chen, LT;Bekaii-Saab, T;Simes, J;Goldstein, D
    贡献者: National Institute of Cancer Research
    摘要: Background: Advanced Gastro-oesophageal Carcinoma (AGOC) has a poor prognosis, and there is no established standard treatment following failure of first- and second-line chemotherapy. Regorafenib (BAY 73-4506) is an investigational oral multi-targeted tyrosine kinase inhibitor (TKI) which targets angiogenic (VEGF, TIE-2), stromal (PDGF-β), and oncogenic (RAF, RET and KIT) receptor tyrosine kinases, and has shown activity in this setting. Single agent regorafenib prolonged progression free survival (PFS) versus placebo across all regions/subgroups in the INTEGRATE randomised phase II trial. Current options in refractory AOGC involves sequencing through chemotherapy with the latest active agent approved being trifluridine/tipiracil, TAS-102. Promising activity in refractory AOGC has been seen with the combination of regorafenib & nivolumab. INTEGRATE IIb – will compare the effectiveness of the combination of regorafenib & nivolumab in pre-treated patients with AGOC to current standard chemotherapy. Trial design: Randomised phase III, open label study with 2:1 randomisation (RegoNivo: standard chemotherapy) and stratification by: 1. Geographic region (Asia vs. Rest of World) 2. Prior VEGF inhibitors (Yes vs No) 3. Prior immunotherapy (Yes vs No) RegoNivo arm will receive 90mg (3x30mg) of regorafenib days 1-21 of each 28-day treatment cycle with intravenous nivolumab 240 mg day 1 of each 14 day cycle until disease progression or prohibitive adverse events as per protocol. The control arm will receive the investigator’s choice of the following chemotherapy; a taxane (paclitaxel or docetaxel), irinotecan or oral trifluridine/tipiracil (TAS102). Primary endpoint: OS. Secondary endpoints: PFS, response rate, quality of life, toxicity, exploratory correlative biomarkers
    日期: 2021-09
    關聯: Annals of Oncology. 2021 Sep;32(Suppl. 5):S1074.
    Link to: http://dx.doi.org/10.1016/j.annonc.2021.08.1547
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000700527702451
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000700527702451.pdf75KbAdobe PDF170检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈